| Literature DB >> 36233230 |
Kaiting Ning1, Baoqiang Yang1, Meng Chen1, Guigui Man1, Shuaiting Liu1, Dong-En Wang1, Huiyun Xu1,2.
Abstract
Bone marrow mesenchymal stem cells (BMSCs) are multi-potent cell populations and are capable of maintaining bone and body homeostasis. The stemness and potential therapeutic effect of BMSCs have been explored extensively in recent years. However, diverse cell surface antigens and complex gene expression of BMSCs have indicated that BMSCs represent heterogeneous populations, and the natural characteristics of BMSCs make it difficult to identify the specific subpopulations in pathological processes which are often obscured by bulk analysis of the total BMSCs. Meanwhile, the therapeutic effect of total BMSCs is often less effective partly due to their heterogeneity. Therefore, understanding the functional heterogeneity of the BMSC subpopulations under different physiological and pathological conditions could have major ramifications for global health. Here, we summarize the recent progress of functional heterogeneity of BMSC subpopulations in physiology and pathology. Targeting tissue-resident single BMSC subpopulation offers a potentially innovative therapeutic strategy and improves BMSC effectiveness in clinical application.Entities:
Keywords: functional heterogeneity of BMSCs; pathological-related BMSC subpopulation; physiological status
Mesh:
Substances:
Year: 2022 PMID: 36233230 PMCID: PMC9570000 DOI: 10.3390/ijms231911928
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 6.208
Figure 1Functional heterogeneity of BMSC subpopulations in physiology and pathology. Physiological conditions include development (embryonic development, adulthood, and aging) and various environmental stresses like loading, microgravity, hypoxia, irradiation, and parathyroid hormone (PTH). Pathological conditions include fracture, osteoporosis, obesity, heterotopic ossification, and acute myeloid leukemia (AML).
Functional heterogeneity of BMSC subpopulations in Physiology.
| Physiological Conditions | BMSC Subpopulations | Functions | References |
|---|---|---|---|
|
| |||
| Embryonic development | Mice: CD105+, Grem1+, 6C3+, LepR+, Axin2+, Gli1+, Osx+, Sox9+, Prx1+ | Supports hematopoiesis: CD105+, 6C3+, and LepR+ | [ |
| Promotes growth and regeneration: Axin2+ and Gli1+ (label cranial SSCs) | [ | ||
| Multi-lineage differentiation: Osx+ (bone marrow), Grem1+ and Sox9+ (cartilage templates), Prx1+ (limb bud) | [ | ||
| Promotes self-renewal and generates the osteochongenesis but no adipocytes and no hematopoietic supportive function: CADM1+ PDPN+ | [ | ||
| Adulthood | Mice: PDGFRα+ (PDGFRa+ Sca-1− CD45− Ter119−), Nestin+ (Nestin-GFP | Promote osteogenesis and support the hematopoiesis: PDGFRα+, Nestin+, Osx+, LepR+, Acan+ Mx1+, Sca1+, CD105+ | [ |
| Label specific bone regions: bone marrow of limb bones (Prx1+); chondrocytes of the resting zone in the growth plate of long bones (PTHrP+); metaphyseal areas (Grem1+, Gli1+, mpMSCs) | [ | ||
| Human: CD105+, CD140a+, CD73+, CD90+, STRO1+, CD271+, CD44+, CD146+ CD271+PDGFRα | Exhibits high CFU-F ability and multi-lineage differentiation potential: CD105+, CD140a+, CD73+, CD90+, STRO-1+, CD271+, CD44+, PDPN+ CD73+ CD164+ CD235− CD45− CD146− Tie2− CD31−, FGFR2+, FGF5+, PLAT+ VCAM1+ | [ | |
| Supports hematopoiesis: CD146+, CD146+ CD271+ PDGFRα | [ | ||
| Label specific bone regions: bone cartilage stromal (CD45− Ter119− Tie2− Thy1− 6C3− CD51+); hypertrophic zones of the growth plate (PDPN+ CD73+ CD164+ CD235− CD45− CD146− Tie2− CD31−) | [ | ||
| Specific functional subpopulation of UC-MSCs: high immune response/regulatory activities (group 1 of UC-MSCs); bone and cartilage growth related group 2 of UC-MSCs | [ | ||
| Aging | Mice: Sca1+, Prx1+, LepR+, LepR+ Notch3+, LepR+ MALPs | Decreases number and impairs paracrine support for hematopoiesis: Sca1+, Prx1+, LepR+, LepR+ Notch3+ | [ |
| Increases the number and promotes adipogenesis: LepR+ MALPs | [ | ||
| Human:CD29+ CD44+ CD90+ CD105+ CD34− CD45− HLA-DR− | Self-renewal related subpopulation: high expression, | [ | |
| Multidirectional differentiation-related subpopulation: high express | [ | ||
| Immune regulation and damage repair related subpopulation: high express | [ | ||
|
| |||
| Loading | Sca-1+ Prx1+, Osx+, CXCL12+, LepR+ osteolectin+ | Responds to loading and participating in bone formation | [ |
| Microgravity | Sca+ CD90.2+, Lin− LepR+, LepR+ osteolectin+ | Declines number and exhibits more quiescence and lower bone anabolism | [ |
| Hypoxia | CD13+ CD29+ CD44+ CD73+ CD90+ CD105+ CD151+ CD34−, PDGFRα+, LepR+, SP7+, 7AAD− CD45− Ter119− Tie2− CD51+ CD105− CD90.2− CD249− CD200− | Exhibits high proliferative activity: CD13+ CD29+ CD44+ CD73+ CD90+ CD105+ CD151+ CD34-, PDGFRα+ and LepR+ | [ |
| Osteogenic and chondrogenic differentiation: SP7+ (also know as Osx+), 7AAD− CD45− Ter119− Tie2− CD51+ CD105− CD90.2− CD249− CD200+ | [ | ||
| Irradiation | Mice: LepR+, Nestin+, CD73+ NGFR | Declines number after irradiation: LepR +, Nestin + | [ |
| Expansion, supports hematopoietic and bone marrow repair: CD73+ NGFR | [ | ||
| Human: CD73+ CD90+ CD105+ CD14− CD34− CD45− HLA-DR− | Exhibits senescence and impairs immunomodulation capacity: CD73+ CD90+ CD105+ CD14− CD34− CD45− HLA-DR− | [ | |
| PTH | LepR+, LepR+ Runx2-GFP | Promotes osteogenic differentiation by promoting osteolectin expression or increasing numbers of type H endothelial cells | [ |
Functional heterogeneity of BMSC subpopulations in pathology.
| Pathological Conditions | BMSC Subpopulations | Functions | References |
|---|---|---|---|
| Fracture | Mx1+ aSMA+, Grem1+, LepR+, Periostin+, and CTSK+, Osx+, Osx+ Sostdc1(−/−) | Expands and actives osteogenesis in response to bone fracture | [ |
| Osteoporosis | Prx1+, Osx+, Thy+/6c3− and LepR+ | Exhibits lower osteogenic potential: Prx1+, Osx+ | [ |
| Actives Thy+ /6c3−, LepR+ can treat osteoporosis | [ | ||
| Heterotopic ossification | Prx1+, PDGFRα+, Hoxa11+ | Upregulates Hif1α or increases VEGFA secretion to promote endochondral ossification to form extraskeletal bone | [ |
| Obesity | IR+ and LepR+ in obese bone marrow; CD45− Sca-1+, Sca1+ CD24+ | Exhibits lower osteogenesis potential and dysregulated metabolism; | [ |
| Impairs osteogenesis capacity through dowregulating Thy-1 expression or upregulating DPP4 level | [ | ||
| AML | Nes+, CD45− Ter119− CD31− LepR+, Osx+, DAPI− CD45− CD235a− CD31− CD146 | Decreases BMSCs number, altered cell shape, and impairs multi-potential | [ |